InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,718.57
(
0.28%
)
US TECH 100
19,312.80
(
0.08%
)
Dow Jones
42,124.65
(
0.15%
)
Brent Oil
73.73
(
-0.01%
)
Bitcoin
62,920.26
(
-0.64%
)
Post# of 964
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

midastouch017

Send PM Follow Ignore
Followers 144
Posts 27707
Boards Moderated 3
Alias Born 02/07/2004

midastouch017

Re: None

Thursday, 03/11/2021 9:30:11 AM

Thursday, March 11, 2021 9:30:11 AM

Post# of 964
Gamida Cell price target lowered to $23 from $25 at Piper Sandler Piper Sandler analyst Edward Tenthoff lowered the firm's price target on Gamida Cell to $23 from $25 and keeps an Overweight rating on the shares. With the Highbridge convertible note, Tenthoff estimates Gamida Cell holds pro forma cash of $202M, which will fund operations into the second half of 2022, the analyst tells investors in a research note. Gamida Cell expects to file an IND for GDA-201 and initiate a Phase I/II study in DLBCL and follicular lymphoma in 2H21, the analyst adds.

https://thefly.com/landingPageNews.php?id=3263168&headline=GMDA-Gamida-Cell-price-target-lowered-to--from--at-Piper-Sandler1615310331
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up